Pharmalittle: Rising Concerns Over Telehealth Fees and Drug Approval Controversies
Health policy experts and legislators are raising concerns over high fees paid by pharmaceutical companies to telehealth providers, potentially violat...
Health policy experts and legislators are raising concerns over high fees paid by pharmaceutical companies to telehealth providers, potentially violat...
Addyi, the controversial 'little pink pill' for low libido in premenopausal women, expanded its FDA approval in December to include all women under 65...